Search Result

Results for "

bone metastasis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) AMPK (2) Apoptosis (7) Bacterial (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) Cathepsin (3) CCR (1) Cholecystokinin Receptor (1) CXCR (1) Drug Derivative (2) Fluorescent Dye (1) HSV (2) Integrin (1) Mitochondrial Metabolism (1) NF-κB (4) NOD-like Receptor (NLR) (2) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PSMA (1) PTHR (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Src (1) VEGFR (2)
By Research Areas:	Cancer (21) Infection (2) Inflammation/Immunology (6) Metabolic Disease (6) Neurological Disease (1)

By Targets:

Acetyl-CoA Carboxylase (2)

AMPK (2)

Apoptosis (7)

Bacterial (1)

Biochemical Assay Reagents (1)

c-Met/HGFR (1)

Cathepsin (3)

CCR (1)

Cholecystokinin Receptor (1)

CXCR (1)

Drug Derivative (2)

Fluorescent Dye (1)

HSV (2)

Integrin (1)

Mitochondrial Metabolism (1)

NF-κB (4)

NOD-like Receptor (NLR) (2)

Nuclear Hormone Receptor 4A/NR4A (1)

p38 MAPK (1)

PSMA (1)

PTHR (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

Src (1)

VEGFR (2)

By Research Areas:

Cancer (21)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (6)

Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-33299

Serpin B9-IN-1 1 Publications Verification BTCA	Biochemical Assay Reagents	Cancer
Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .

HY-B0515

Ibandronate Sodium Monohydrate 1 Publications Verification BM-210955; RPR-102289A	Apoptosis	Metabolic Disease Cancer
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER ⁺ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .

HY-P9992

Pelgifatamab BAY-2315497; PSMA-TTC	PSMA Apoptosis	Cancer
Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC₅₀ of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .

HY-P99781

Plozalizumab MLN-1202	CCR	Inflammation/Immunology Cancer
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-N2098

Obtusifolin 4 Publications Verification	NF-κB	Cancer
Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway . Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein .

HY-N0772

Isomangiferin 4 Publications Verification	VEGFR NOD-like Receptor (NLR) NF-κB Bacterial AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative	Infection Metabolic Disease Inflammation/Immunology Cancer
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing .

HY-B0515B

Ibandronate Sodium 1 Publications Verification	Apoptosis	Metabolic Disease Cancer
Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .

HY-136990

GLPG0259	p38 MAPK	Cancer
GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .

HY-164634

CLIK-148	Cathepsin Cholecystokinin Receptor	Neurological Disease Metabolic Disease Cancer
CLIK-148 is a highly selective, irreversible and orally active cysteine protease inhibitor, primarily targeting Cathepsin L. CLIK-148 effectively inhibits the Cathepsin L-dependent degradation of HMG-CoA reductase in the endoplasmic reticulum (ER) membrane. CLIK-148 inhibits the processing of proCCK by Cathepsin L, thereby reducing the production of CCK8 (HY-P0093). CLIK-148 inhibits the degradation of type I collagen by osteoclasts' secreted Cathepsin L, reducing tumor-induced bone metastasis and malignant hypercalcemia. CLIK-148 can be used for the studies of bone metabolism disorders and regulation of neuropeptide processing .

HY-16498

Tigapotide PCK-3145	Apoptosis PTHR	Metabolic Disease Cancer
Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .

HY-P2153

Maraciclatide	Integrin	Inflammation/Immunology Cancer
Maraciclatide is a synthetic molecule that binds with high affinity to α_vβ₃ and α_vβ₅ integrins via the RGD peptide. Maraciclatide can be used to detect bone metastasis, breast tumors, vascular disease and rheumatoid arthritis in animal models. Maraciclatide can be studied in research on angiogenesis and inflammation .

HY-P991660

ARGX-111	c-Met/HGFR	Cancer
ARGX-111 is an anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers .

HY-125064

AP22408	Src	Cancer
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC₅₀ value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .

HY-D2132

Sulfo-Cy5.5-ALN	Fluorescent Dye	Cancer
Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis .

HY-144813

Gü2602	Cathepsin	Inflammation/Immunology Cancer
Gü2602 is a potent, reversible cathepsin K (CatK) inhibitor with a K_i of 0.013 nM for mature CatK (mCatK). Gü2602 suppresses the autocatalytic activation of the cathepsin K zymogen .

HY-N2098R

Obtusifolin (Standard)	Reference Standards NF-κB	Cancer
Obtusifolin (Standard) is the analytical standard of Obtusifolin. This product is intended for research and analytical applications. Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway . Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein .

HY-B0515R

Ibandronate Sodium Monohydrate (Standard) BM-210955 (Standard); RPR-102289A (Standard)	Reference Standards Apoptosis	Cancer
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate (HY-B0515). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER ⁺ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .

HY-144812

Gü1303	Cathepsin	Inflammation/Immunology Cancer
Gü1303 is a potent, reversible, slow-binding cathepsin K (CatK) inhibitor with a K_i of 0.91 nM for mature CatK (mCatK). Gü1303 suppresses the autocatalytic activation of the cathepsin K zymogen .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

HY-N0772R

Isomangiferin (Standard)	Reference Standards VEGFR NF-κB NOD-like Receptor (NLR) AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative	Infection Metabolic Disease Inflammation/Immunology Cancer
Isomangiferin (Standard) is the analytical standard of Isomangiferin (HY-N0772). This product is intended for research and analytical applications. Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.

HY-P991744

Anti-Mouse CXCR4 Antibody (Cx4Mab-1)	CXCR	Cancer
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .

Sulfo-Cy5.5-ALN	Fluorescent Dyes
Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis .

Cat. No.	상품명	Target	Research Area